Therapeutic Potential of Cannabinoids in Glaucoma – Hit or Myth? - A Review
Introduction: Glaucoma is a leading cause of irreversible blindness, characterized by elevated intraocular pressure (IOP) that damages the optic nerve. Current treatments mainly focus on reducing IOP, but some patients do not respond adequately to conventional therapies. Cannabinoids, particularly...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nicolaus Copernicus University in Toruń
2024-11-01
|
| Series: | Quality in Sport |
| Subjects: | |
| Online Access: | https://apcz.umk.pl/QS/article/view/56053 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849221269550006272 |
|---|---|
| author | Julia Górny Alicja Kapciak Tomasz Forenc Jonasz Jurek Aleksandra Pelczarska Jaromir Hunia Marcin Komorowski Rafał Kaczorowski Michał Janiszewski |
| author_facet | Julia Górny Alicja Kapciak Tomasz Forenc Jonasz Jurek Aleksandra Pelczarska Jaromir Hunia Marcin Komorowski Rafał Kaczorowski Michał Janiszewski |
| author_sort | Julia Górny |
| collection | DOAJ |
| description |
Introduction: Glaucoma is a leading cause of irreversible blindness, characterized by elevated intraocular pressure (IOP) that damages the optic nerve. Current treatments mainly focus on reducing IOP, but some patients do not respond adequately to conventional therapies. Cannabinoids, particularly Δ9-tetrahydrocannabinol (Δ9-THC), have been investigated as potential adjunctive treatments for glaucoma. Studies have shown varying effects of cannabinoids on IOP regulation, though their precise mechanisms remain unclear.
Aim of Study: This study aims to evaluate the therapeutic potential of cannabinoids in the treatment of glaucoma by examining their effects on IOP, their mechanisms of action, and the risks and benefits associated with their use.
Material and methods: A comprehensive literature review of studies on the therapeutic potential of cannabinoids in glaucoma was conducted using the PubMed database.
Results and Conclusions: Cannabinoids, especially Δ9-THC, have demonstrated the ability to reduce IOP in both healthy individuals and glaucoma patients. However, the effect is typically short-lived, lasting only 3-4 hours. The efficacy of cannabinoids in reducing IOP is influenced by the method of administration (oral, intravenous, inhalation) and the delivery system used for topical application. Despite some promising results, the use of cannabinoids as a mainstream glaucoma treatment is limited by factors such as the short duration of action, the potential for addiction, and the occurrence of adverse effects like tachycardia, hypotension, and cognitive impairment. Although cannabinoids offer a unique approach to glaucoma management, further research is necessary to address these limitations and determine their long-term therapeutic viability.
|
| format | Article |
| id | doaj-art-06fe1ecb129e4302a13a91e02f46f3c9 |
| institution | Kabale University |
| issn | 2450-3118 |
| language | English |
| publishDate | 2024-11-01 |
| publisher | Nicolaus Copernicus University in Toruń |
| record_format | Article |
| series | Quality in Sport |
| spelling | doaj-art-06fe1ecb129e4302a13a91e02f46f3c92024-11-17T08:08:41ZengNicolaus Copernicus University in ToruńQuality in Sport2450-31182024-11-013210.12775/QS.2024.32.56053Therapeutic Potential of Cannabinoids in Glaucoma – Hit or Myth? - A ReviewJulia Górny0Alicja Kapciak1Tomasz Forenc2Jonasz Jurek 3Aleksandra Pelczarska4Jaromir Hunia5Marcin Komorowski6Rafał Kaczorowski7Michał Janiszewski8Mazovian "Bródnowski" Hospital, Ludwika Kondratowicza 8, 03-242 Warsaw, PolandNational Medical Institute of the Ministry of the Interior and Administration, Wołoska 137, 02-507 Warsaw, PolandMedical University of Warsaw, Żwirki i Wigury 61, 02-091 Warsaw, PolandNational Medical Institute of the Ministry of the Interior and Administration, Wołoska 137, 02-507 Warsaw, PolandMedical University of Warsaw, Żwirki i Wigury 61, 02-091 Warsaw, PolandNational Medical Institute of the Ministry of the Interior and Administration, Wołoska 137, 02-507 Warsaw, PolandMiędzylesie Specialist Hospital, Bursztynowa 2, 04-749 Warsaw, PolandMazovian "Bródnowski" Hospital, Ludwika Kondratowicza 8, 03-242 Warsaw, PolandMazovian "Bródnowski" Hospital, Ludwika Kondratowicza 8, 03-242 Warsaw, Poland Introduction: Glaucoma is a leading cause of irreversible blindness, characterized by elevated intraocular pressure (IOP) that damages the optic nerve. Current treatments mainly focus on reducing IOP, but some patients do not respond adequately to conventional therapies. Cannabinoids, particularly Δ9-tetrahydrocannabinol (Δ9-THC), have been investigated as potential adjunctive treatments for glaucoma. Studies have shown varying effects of cannabinoids on IOP regulation, though their precise mechanisms remain unclear. Aim of Study: This study aims to evaluate the therapeutic potential of cannabinoids in the treatment of glaucoma by examining their effects on IOP, their mechanisms of action, and the risks and benefits associated with their use. Material and methods: A comprehensive literature review of studies on the therapeutic potential of cannabinoids in glaucoma was conducted using the PubMed database. Results and Conclusions: Cannabinoids, especially Δ9-THC, have demonstrated the ability to reduce IOP in both healthy individuals and glaucoma patients. However, the effect is typically short-lived, lasting only 3-4 hours. The efficacy of cannabinoids in reducing IOP is influenced by the method of administration (oral, intravenous, inhalation) and the delivery system used for topical application. Despite some promising results, the use of cannabinoids as a mainstream glaucoma treatment is limited by factors such as the short duration of action, the potential for addiction, and the occurrence of adverse effects like tachycardia, hypotension, and cognitive impairment. Although cannabinoids offer a unique approach to glaucoma management, further research is necessary to address these limitations and determine their long-term therapeutic viability. https://apcz.umk.pl/QS/article/view/56053glaucomacannabinoidscannabinoid receptorsintraocular pressure |
| spellingShingle | Julia Górny Alicja Kapciak Tomasz Forenc Jonasz Jurek Aleksandra Pelczarska Jaromir Hunia Marcin Komorowski Rafał Kaczorowski Michał Janiszewski Therapeutic Potential of Cannabinoids in Glaucoma – Hit or Myth? - A Review Quality in Sport glaucoma cannabinoids cannabinoid receptors intraocular pressure |
| title | Therapeutic Potential of Cannabinoids in Glaucoma – Hit or Myth? - A Review |
| title_full | Therapeutic Potential of Cannabinoids in Glaucoma – Hit or Myth? - A Review |
| title_fullStr | Therapeutic Potential of Cannabinoids in Glaucoma – Hit or Myth? - A Review |
| title_full_unstemmed | Therapeutic Potential of Cannabinoids in Glaucoma – Hit or Myth? - A Review |
| title_short | Therapeutic Potential of Cannabinoids in Glaucoma – Hit or Myth? - A Review |
| title_sort | therapeutic potential of cannabinoids in glaucoma hit or myth a review |
| topic | glaucoma cannabinoids cannabinoid receptors intraocular pressure |
| url | https://apcz.umk.pl/QS/article/view/56053 |
| work_keys_str_mv | AT juliagorny therapeuticpotentialofcannabinoidsinglaucomahitormythareview AT alicjakapciak therapeuticpotentialofcannabinoidsinglaucomahitormythareview AT tomaszforenc therapeuticpotentialofcannabinoidsinglaucomahitormythareview AT jonaszjurek therapeuticpotentialofcannabinoidsinglaucomahitormythareview AT aleksandrapelczarska therapeuticpotentialofcannabinoidsinglaucomahitormythareview AT jaromirhunia therapeuticpotentialofcannabinoidsinglaucomahitormythareview AT marcinkomorowski therapeuticpotentialofcannabinoidsinglaucomahitormythareview AT rafałkaczorowski therapeuticpotentialofcannabinoidsinglaucomahitormythareview AT michałjaniszewski therapeuticpotentialofcannabinoidsinglaucomahitormythareview |